This is an international site for KISQALI® (ribociclib)
and is intended for healthcare professionals outside the US.
This is an international site for KISQALI® (ribociclib)
and is intended for healthcare professionals outside the US.
The information on this site is not country-specific and may contain details that are outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
Visit your local HCP portal for further country specific information
This website is intended for Health Care Professionals (HCPs) outside the US, and Switzerland, and UK. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information. By clicking continue you are confirming that you are an HCP.
Real-world and diverse population studies confirm that KISQALI is well tolerated with a consistent safety profile in a broad range of HR+/HER2– ABC patients. (2,3)
* Please consult your local Summary of Product Characteristics for the full KISQALI safety and tolerability profile.
† Febrile neutropenia was reported in 1.7% of patients exposed to KISQALI in the phase III clinical studies. (1)
By Novartis AG
© 2025 ǀ FA-11471125-2 ǀ October 2025
Use of this website is subject to our Terms of Use